SparkMind (Nanjing) Technology Co., Ltd. (“SparkMind”) is a specialized contract research organization (CRO) dedicated to neuroscience and cardiovascular research. Founded in Nanjing in 2025, SparkMind provides integrated technology platforms that combine electrophysiology with advanced biological microscopy imaging for pharmaceutical companies and research institutions worldwide.
Our service model balances standardized experimental workflows with flexible, project-specific customization, supporting drug discovery, mechanism-of-action studies, and safety evaluation. Built on core platforms in electrophysiology and tissue/cell imaging, SparkMind has established a “cross-system, single-platform” research paradigm designed to improve experimental efficiency, data consistency, and cross-study comparability. Our core technical team is composed entirely of PhD-level scientists trained with a strong focus on data quality, traceability, and internationally aligned operational standards, supporting both drug development programs and high-impact scientific publications.
Founder Background
Yu Chen, PhD (Peking University), is a co-founder of SparkMind (Nanjing) Technology Co., Ltd. His doctoral research focused on the integration of electrophysiology and imaging technologies, with particular emphasis on high-throughput voltage imaging approaches for neuroscience and cardiovascular drug discovery. In contrast to traditional single-cell patch-clamp techniques, his work pioneered and validated voltage probe–based imaging strategies capable of recording electrical activity from hundreds to thousands of cells simultaneously, substantially increasing throughput and scalability.
Following his PhD training, Dr. Chen co-founded SparkMind together with Dr. Yuan Li, also a Peking University PhD with combined clinical and industry experience. Within a short period, SparkMind established operations in the Nanjing Jiangbei New Area. Under the leadership of Dr. Li and Dr. Chen, SparkMind has successfully transitioned from early-stage development to operational maturity, with its electrophysiology and biological microscopy platforms becoming effective enablers of innovative drug discovery.
Core Technologies
In cardiac safety assessment, SparkMind places strong emphasis on hERG channel screening. Using patch-clamp and complementary electrophysiological techniques aligned with international best practices, we generate kinetic and IC₅₀ data under near-physiological temperature conditions to support early risk mitigation and lead compound selection.
SparkMind has established robust capabilities in the isolation, culture, and imaging of primary cells, enabling preservation of native electrophysiological and structural characteristics in vitro. Through confocal microscopy and electron microscopy, we assess calcium signaling, mitochondrial function, and overall structural integrity, providing visual and mechanistic insights for cardiovascular drug discovery and safety evaluation.
By integrating acute brain slice and neuronal preparations with patch-clamp recording and microscopy imaging, SparkMind investigates neural activity from single cells to functional circuits across multiple brain regions, including the hippocampus, cortex, and striatum. We analyze neuronal excitability, synaptic transmission, and synaptic plasticity, and also support primary neuronal cultures such as dorsal root ganglion (DRG) sensory neurons, delivering functional data for neuroscience and pain drug discovery and mechanism studies.
In cellular imaging, SparkMind has developed a comprehensive phenotypic profiling platform encompassing high-content imaging, super-resolution microscopy, and electron microscopy. This platform covers in vitro model development, sample preparation, antibody validation, imaging execution, and data analysis, supporting both fundamental mechanism research and functional validation and safety assessment in drug development.
